Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR T-Cell therapy targets tough lymphoma

NCT ID NCT07670260

Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of immune cell therapy called GoFast CD19 CAR T-cells in 9 adults with relapsed or refractory large B-cell lymphoma. Participants receive chemotherapy followed by an infusion of their own modified immune cells. The study aims to see if the treatment is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GoFast CD19 CAR T-cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
What could go wrong
This is a very early, small trial with only 9 participants, so results may not apply widely. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 9 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Histologically or cytologically confirmed primary refractory or relapsed/progressive large B-cell lymphoma. * Expected survival of more than 3 months. * CD19-positive B-cell lymphoma confirmed by flow cytometry or immunohistochemistry. * ECOG performance status of 0 to 2 or KPS score greater than 80. * Adequate venous access for leukapheresis or peripheral blood collection, with no contraindication to blood cell separation. * White blood cell count ≥ 1 × 10\^9/L and lymphocyte count ≥ 0.3 × 10\^9/L. * INR \< 1.7 or prothrombin time prolonged by less than 4 seconds above the normal value. * ALT and AST ≤ 2.5 × upper limit of normal. * Total bilirubin ≤ 2.0 mg/dL, equivalent to 34.2 μmol/L. * Able to understand and voluntarily sign the written informed consent form. Exclusion Criteria: * Pregnant or breastfeeding women. * Active hepatitis B virus or hepatitis C virus infection. * HIV/AIDS infection. * Any uncontrolled active infection. * Systemic corticosteroid use within 2 weeks before signing informed consent, except inhaled corticosteroids. * Active cardiac disease requiring treatment or poorly controlled hypertension. * Unstable or active ulcer disease or gastrointestinal bleeding. * History of organ transplantation or currently awaiting organ transplantation. * Central nervous system involvement by lymphoma. * Current participation in another clinical trial. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for this clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.